Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Viking Therapeutics"


25 mentions found


An AI model that is trying to use machine learning to pick stocks is optimistic about the outlook for some names in volatile sectors over the next month. IFi AI is a company aimed at individual investors that identifies stocks with potential upside based on a blend of fundamental, technical and news data. The stock in the model's highest confidence bracket with the most projected upside is a similarly named company — Marathon Digital . But instead of being an energy company, Marathon Digital is a bitcoin miner. CNBC senior analyst and commentator Ron Insana is the CEO if iFi AI, which launched in March .
Persons: IBM's Watsonx, , Kilroy, Ron Insana Organizations: Marathon Oil, ConocoPhillips, Marathon, iFi, Kilroy Realty, BridgeBio Pharma, Viking Therapeutics, Therapeutics, CNBC Locations: California
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: You don't want to be in Hawaiian Electric, says Jim Cramer'Mad Money' host Jim Cramer weighs in on stock including: Viking Therapeutics, H.B. Fuller, AstraZeneca, and Hawaiian Electric.
Persons: Jim Cramer, Fuller Organizations: Viking Therapeutics, AstraZeneca, Electric
Viking Therapeutics : "I say you need to be in Eli Lilly. Step your game up, partner." AstraZeneca : "This is an amazing team that they've got at AstraZeneca now, and they've got fantastic formulations in oncology, but also heart. And they have a GLP-1 kind of thing going on, but it's a little far removed...You've got a winner with AstraZeneca."
Persons: Eli Lilly, they've, You've Organizations: Viking Therapeutics, AstraZeneca
Eli Lilly dips: Shares of Eli Lilly are sitting out the rally on news that Swiss pharmaceutical firm Roche 's experimental obesity drug demonstrated promise in a Phase 1 study. "Doug McMillon, the CEO of Walmart, made the point repeatedly that the company's success this quarter came from lower prices," Jim Cramer said. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Eli Lilly, Roche, It's, inflect, We're, Doug McMillon, Estee Lauder, Jim, Jim Cramer's Organizations: CNBC, Viking Therapeutics, Club, Deere, Walgreens Boots, Walmart, Costco, Materials, Jim Cramer's Charitable Locations: Swiss, Amgen, China
Amgen is among the leaders of a pack of drugmakers racing to join the market with their own weight loss treatments. Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders' injections. Novo Nordisk and Eli Lilly are also working on new weight loss drugs. The competition for a slice of the weight loss market has only grown more fierce in recent months. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.
Persons: NOVO.B, Scott Olson, Eli Lilly, Nordisk's Wegovy, Eli Lilly's Zepbound, Amgen, William Blair, Matt Phipps, Bob Bradley, Boehringer Ingelheim, Phipps, Zepbound, Chris Schott, MariTide, Mario Tama, he's, Eli Lilly drugs, CagriSema, Eli Lilly’s, Brendan McDermid, Boehringer, Ingelheim, survodutide, Pascal Soriot, Christopher Furlong, dealmaking, David Denton Organizations: New, Halstead Pharmacy, Getty, Novo Nordisk, Nordisk's, William Blair & Company, CNBC, Therapeutics, AstraZeneca, Zealand Pharma, MariTide, Reuters, GLP, Pfizer, Eccogene Locations: Chicago , Illinois, Novo, Amgen, Thousand Oaks , California, New York City, U.S, Zealand, Macclesfield
The Nasdaq sank 2% on Friday as Netflix dropped nearly 11% post-earnings and Club stock Nvidia fell 10%, entering bear market territory but still up more than 50% in 2024. Following a much stronger-than-expected March retail sales report last month, fresh economic data and six Club stock earnings will take center stage in the week ahead. While lower rates may help stock multiples, that is not a sustainable path to higher equity prices over time. Earnings : The latest quarterly reporting season is starting to ramp into high gear with six Club names set to report next week. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.
Persons: Dow, Jerome Powell, Jim Cramer, Mark, Meta, Bing, Ford, Vimal, Lockheed Martin, Clark, Philip Morris, Sherwin, Williams, Baker Hughes, Lam, Northrop, Dr Pepper, CARR, Edwards Lifesciences, Jim Cramer's, Jim, Michael M Organizations: Nasdaq, Netflix, Nvidia, Dow Jones, Federal, Fed, Hamas, Gross, Google, Reality Labs, General Motors, Honeywell, Microsoft, Verizon Communications, Albertsons Companies, SAP, Cadence Design Systems, United Parcel Service, General Electric, GE, PepsiCo, Lockheed, Spotify Technology, RTX Corporation, JetBlue Airways, Halliburton, HAL, Philip Morris International, Quest Diagnostics, Texas Instruments, Seagate Technology, Mattel, Veralto Corporation, Boeing, General Dynamics, Boston, Hilton, Fisher, Otis Worldwide, IBM, Grill, Viking Therapeutics, Lam Research, Whirlpool, WM, Honeywell International, Royal Caribbean Cruises, American Airlines, Altria, Newmont, Caterpillar, Southwest Airlines, Myers Squibb, AstraZeneca, Mobileye, Northrop Grumman, CNBC, Comcast, Merck, Dow Inc, Carrier Global, Union Pacific, Intel, Western, Mobile, L3Harris Technologies, Exxon Mobil, Chevron, Colgate, Palmolive, HCA Healthcare, Charter Communications, Newell Brands, Jim Cramer's Charitable, Traders, New York Stock Exchange, Santiago, Getty Locations: Israel, Iran, Ukraine, destocking, China, Cleveland, Freeport, McMoRan, Kimberly, Masco, Bristol, New York City
Weight-loss drugs like Ozempic, Wegovy, and Mounjaro are all the rage, and investors are noticing. Since launching in November, the Tema Obesity and Cardiometabolic ETF (HRTS) is up 24%, crushing the S&P 500's 14.8% returns over the same period. Pot and his colleagues at Tema are bullish on the weight-loss drug stocks due to the wave of demand they see coming. Novo Nordisk estimates that only 2% of obesity cases are being treated by weight-loss drugs, Pot said. 4 weight-loss drug stocks to watchPot listed two larger stocks and two smaller ones in the space.
Persons: Maurits Pot, Janus Henderson, Pot, Goldman Sachs, Geoff Meacham, Charles Barkley, Elon Musk, Whoopi Goldberg, Eli Lilly, Lilly Organizations: VanEck Pharmaceutical, Business, World Health Organization, Novo Nordisk, Bank of America, Bank, Nordisk, FDA, Amazon, Therapeutics, Zealand Pharma Locations: Tema, GLP, Danish, it's
Robinhood — Shares of the brokerage firm jumped more than 6% after unveiling its Robinhood Gold Card, a credit card where cash back can be deposited into a brokerage account. Concentrix — Shares slipped nearly 4% on the back of disappointing fiscal second-quarter earnings guidance. The customer experience technology company also reiterated its full-year outlook for 2024. In the prior session , the stock popped more than 15% on promising trial results for a weight loss pill. Trump Media & Technology Group — Shares of former President Donald Trump's social media company climbed nearly 14% after making its debut as a publicly traded company a day earlier.
Persons: Krispy, McDonald's, Morgan Stanley, Donald Trump's, — CNBC's Michelle Fox, Sarah Min, Jesse Pound Organizations: GameStop, Moderna, Blackstone Life Sciences, Viking Therapeutics, Deutsche Bank, Trump Media & Technology, Merck, Food and Drug Administration, FactSet
Viking Therapeutics shares jumped more than 25% on Tuesday after the company said its experimental weight loss pill showed positive results in a small study and will enter the next stage of development later this year. The study results add to the excitement around the drugmaker's prospects in the budding weight loss drug market. Based on Tuesday's results, Viking plans to start a phase two trial of its weight loss pill later this year. Weight loss for those patients ranged up to 3.6% higher than those who received a placebo. Viking CEO Brian Lian said during a conference call on Tuesday that it's unclear "how durable" the weight loss is.
Persons: Eli Lilly, Viking, Brian Lian Organizations: Viking Therapeutics, Novo Nordisk, Viking
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Finally, Viking Therapeutics soared more than 25% after reporting encouraging Phase 1 results of its oral weight loss pill. The data showed up to 5.3% weight loss at 28 days. Its Phase 2 results up to 14.7% mean weight loss at 36 weeks. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .
Persons: Jim Cramer, Larry Fink, It's, Wedbush, Jim, Eli Lilly, Jim Cramer's Organizations: CNBC, BlackRock, Census Bureau, Social Security, Microsoft, Justice Department, Viking Therapeutics
Krispy Kreme — Krispy Kreme popped nearly 30% and headed for its best day on record. Trump Media & Technology Group — Shares of former President Donald Trump's social media company surged 35% after it began trading on the Nasdaq . Trump Media completed its merger with shell company Digital World Acquisition Corp . McCormick — The stock jumped 10% after the spice maker topped earnings and revenue expectations for its fiscal first quarter. Reddit — Reddit popped about 15% as investors continued buying up the social media stock following its Thursday debut on the New York Stock Exchange .
Persons: Kreme, McDonald's, Donald Trump's, McCormick, Morgan Stanley, Alex Harring, Michelle Fox, Jesse Pound, Pia Singh Organizations: Trump Media & Technology, Nasdaq, Trump Media, Revenue, New York Stock Exchange, Viking Therapeutics, Seagate Technology, Micron Technology, Mizuho Securities, UPS —, UPS, JPMorgan Locations: FactSet
Mario Tama | Getty ImagesAmgen is taking a new approach as it tries to stand out in a crowded field of drugmakers racing to develop the next blockbuster weight loss drug. It's too early to say how competitive Amgen will be in the budding weight loss drug space, which Novo Nordisk and Eli Lilly have so far dominated. Goldman Sachs also projects that between 10 million and 70 million Americans will be taking weight loss drugs by 2028. The sustained weight loss in Amgen's study appears to contrast with results seen in clinical trials on Zepbound and Wegovy. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.
Persons: Mario Tama, Eli Lilly, Goldman Sachs, Zepbound, Eli Lilly's, Amgen's MartiTide, Caroline Apovian, Apovian, Joe Buglewicz, MariTide, Holly Lofton, Eli Lilly’s, Brendan McDermid, Reuters Amgen's, William Blair, Matt Phipps, Phipps Organizations: Getty, Novo Nordisk, Pfizer, Viking Therapeutics, Therapeutics, Zealand Pharma, Boehringer, Center, Weight Management, Wellness, Brigham, Women's, Washington Post, NYU Langone Health, Reuters, William Blair & Company, CNBC Locations: Thousand Oaks , California, Oaks , California, Novo, New York City, U.S
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Jim Cramer said the stock is a must-own tied to energy and oil. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .
Persons: Jim Cramer, Dow, Eaton, Locker, Jerome Powell, Jim, Thomas Jorden, Eli Lilly, Lilly, Jim Cramer's Organizations: CNBC, Nasdaq, Nvidia, Broadcom, Costco, Capitol, Coterra Energy, Management, Wall, UBS, Club, Therapeutics Locations: AVGO, FL
In this article VKTX Follow your favorite stocks CREATE FREE ACCOUNTCr | Istock | Getty ImagesBiotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market. Their treatments sparked the weight loss drug industry gold rush over the past year despite their hefty price tags and barriers to insurance coverage. It's too early to say whether Viking's drug could have an edge over existing or developing weight loss treatments. The pharmaceutical giant could also launch a slate of other weight loss treatments over the next few years that may have advantages over Zepbound, whether they offer more weight loss or convenience. That could give Viking the commercial and manufacturing capabilities needed to compete in the weight loss drug market.
Persons: Eli Lilly, Eli Lilly's Zepbound, Viking, Goldman Sachs, Eli Lilly’s, Brendan Mcdermid, GLP, Brian Lian, William Blair, Andy Hsieh, Hsieh, Eli Lilly's, Jefferies, Akash Tewari, doesn't, Mike Segar, Lian, William Blair's Hsieh, Oppenheimer, Jay Olson Organizations: Getty Images Biotech, Viking Therapeutics, Novo Nordisk, Reuters, Viking, Novo, U.S . Food, Drug Administration, Company, Deutsche Bank, CNBC Locations: New York City, Branchburg , New Jersey
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.
Persons: Jim Cramer, Dow, Jim, Chris Danely, Cramer, Eaton, Eli Lilly, Lilly, Jim Cramer's Organizations: CNBC, Dow, Nasdaq, Semiconductor, Citi, Broadcom, Nvidia, Devices, Micron, Dell Technologies, Autodesk, Novo Nordisk, Abbott Laboratories, Novo, Viking, Jim Cramer's Charitable
Biotech company Viking Therapeutics saw stock prices double after a report on weight loss drug VK2735. The new drug could lead to even more weight loss at a faster pace than Ozempic or Mounjaro. Viking Therapeutics, a small California-based biotech company, shared the topline results from a mid-stage trial of its drug VK2735 on February 27. AdvertisementHowever, the early results of clinical trials suggest it could be on par to offer even more weight loss in less time than its competitors. How Viking Therapeutics' weight-loss drug worksVK2735 mimics two hormones that affect weight control.
Persons: , Eli Lilly, GIP, VK2735 Organizations: Biotech, Viking Therapeutics, Service, Novo Nordisk, Washington Post, Therapeutics, Viking Locations: California
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Eli Lilly shares fell 1% on Wednesday following a similar drop in the prior session. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Salesforce, Jim, Let's, Eli Lilly, Jim Cramer's Organizations: CNBC, TJX Companies, Management, Therapeutics Locations: GLP
CNBC's Jim Cramer on Tuesday downplayed the competitive risk to Eli Lilly — a longtime holding in his Charitable Trust — presented by Viking Therapeutics ' new weight-loss drug data. Currently, Eli Lilly and Wegovy maker Novo Nordisk are the dominant players in the GLP-1 category. Eli Lilly and Novo Nordisk are far larger, worth around $733 billion and $550 billion as of Tuesday. Eli Lilly shares, among the best performers in the S & P 500 this year, fell slightly Tuesday. Cramer's Charitable Trust, the portfolio used by the CNBC Investing Club , has long owned Eli Lilly.
Persons: CNBC's Jim Cramer, Eli Lilly —, , Eli Lilly, Cramer, Eli Lilly's tirzepatide, David Ricks, Lilly's, retatrutide Organizations: Viking Therapeutics, Novo Nordisk, Viking, Leerink Partners, Charitable Trust, CNBC Locations: Lilly
VKTX YTD mountain Viking shares year to date Then, Viking shares more than doubled in trading on Tuesday, putting the stock on pace to report a more than 300% year-to-date gain, after the company said its GLP-1/GIP receptor agonist VK2735 hit all its primary goals in a phase 2 clinical trial. The Tema Cardiovascular and Metabolic ETF (HRTS) , which is up 12% year to date, owns Novo, Lilly and Viking. Still early days Some analysts and investors admit it is still very early days for obesity treatment and many questions remain to be answered. "We continue to expect above consensus growth in the space, as we are bullish on adoption from payers and broader obesity uptake," Meacham wrote. For obesity only, Lilly has already gained a 38% share, despite only being in the market for 13 weeks, he said.
Persons: Eli Lilly, Geoff Meacham, Meacham, Lilly, Yuri Khodjamirian, Khodjamirian, Jeff Jonas, Becton Dickinson, Novo, BofA's Meacham, What's, Tema's, it's, Gabelli's Jonas, he's, William Blair, Andy Hsieh, Hsieh Organizations: Novo Nordisk, Bank of America, Centers for Disease Control, Zealand Pharma, Viking Therapeutics, Zealand, Food and Drug Administration, Novo, Metabolic, Therapeutics, Pharmaceuticals, Rock, AstraZeneca, Roche, Gabelli Funds, FDA, Viking, Merck, Pfizer Locations: U.S, Tema, Novo Nordisk's, GLP, Lilly
Shares of Viking Therapeutics soared more than 80% in premarket trading Tuesday after the company's experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say could grow into a $100 billion market by the end of the decade. Separately, the company said it expects to release early-stage trial data on an oral version of its weight loss drug. Viking Therapeutics' drug targets GLP-1 and another hormone called GIP. Those are the same hormones that Eli Lilly's weight loss and diabetes drugs, Zepbound and Mounjaro, target.
Persons: Brian Lian, Eli Lilly's Organizations: Viking Therapeutics, Viking, Food and Drug Administration
Unity Software — Shares tumbled 15% after the video game developer forecasted that adjusted EBITDA would come in below analysts' expectations for the current quarter. Analysts polled by FactSet had expected $113 million in EBITDA, while Unity is expecting only between $45 million to $50 million. Workday's adjusted earnings came in at $1.57 a share, higher than the $1.47 expected by analysts polled by LSEG. AutoZone's earnings of $28.89 per share topped the $26.28 per share analysts had anticipated, according to LSEG. The company's $3.85 billion revenue was also higher than the anticipated $3.84 billion.
Persons: FactSet, LSEG, CarGurus, they'll, AutoZone, EBITDA, Wells, — CNBC's Michelle Fox, Tanaya Macheel, Sarah Min, Jesse Pound Organizations: Unity, LSEG, FactSet, PPG, Barclays, PPG Industries, FDA Locations: EBITDA, Cava, Wells Fargo, U.S, Canada
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. But Jim Cramer said the biggest theme in the market right now is cybersecurity. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .
Persons: Jim Cramer, Jim, Eli Lilly, Jim assuaged, it's, Wells Fargo, Jim Cramer's Organizations: CNBC, Palo Alto Networks, Viking Therapeutics
Norwegian Cruise Line — The cruise ship operator soared 18% on strong forward guidance. Unity expects adjusted EBITDA to range between $45 million and $50 million, versus the $113 million expected by analysts polled by FactSet. Viking Therapeutics — The clinical-stage biotech soared more than 90% after fulfilling primary and secondary endpoints in its Phase 2 GLP-1 study. Earnings came in at $1.57 per share, beating expectations of $1.47 per share, according to LSEG, formerly known as Refinitiv. Revenue of $1.92 billion matched analysts' expectations.
Persons: Viking, LSEG, Cava, Wells, Duolingo, CarGurus, — AutoZone, Microstrategy, , Sarah Min, Michelle Fox, Alex Harring, Jesse Pound, Yun Li Organizations: Cruise, Unity Software, FactSet, Therapeutics, Hess Corporation, Chevron, Exxon Mobil, China's, Offshore Oil Corp, Hess, Bank of America Securities, Seaport Research Partners, CleanSpark Locations: Cava
Cramer’s Stop Trading: Viking Therapeutics
  + stars: | 2024-02-27 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCramer’s Stop Trading: Viking TherapeuticsCNBC’s Jim Cramer explains why he is keeping an eye on shares of Viking Therapeutics.
Persons: Jim Cramer Organizations: Therapeutics, Viking Therapeutics
Michael Siluk | UCG | Getty ImagesBoehringer IngelheimBoehringer Ingelheim is developing a weight loss drug with Danish biotech firm Zealand Pharma. Some popular weight loss drugs such as Novo Nordisk's Wegovy only target GLP-1. Terns PharmaceuticalsSmaller drugmakers are developing their own weight loss drugs. Quirk acknowledged that it may be difficult for Terns to set its pill apart from other weight loss drugs. Viking Therapeutics expects to release mid-stage trial data on its weight loss injection in the first half of the year.
Persons: Michael Siluk, Boehringer Ingelheim, Erin Quirk, Quirk, it's, Eli Lilly's, Roger Song Organizations: UCG, Getty, Zealand Pharma, Nordisk's, Drug Administration, JPMorgan Healthcare Conference, Pharmaceuticals, Terns Pharmaceuticals, GLP, Viking Therapeutics, Therapeutics, Jefferies Locations: Viking
Total: 25